Petauri PACT Executive Briefings - 3-Minute Market Insights
Welcome to the Petauri PACT Executive Briefing, where in 3-minutes we highlight healthcare’s critical market access issues, policies, challenges, or trends. This resource offers condensed, 3-minute episodes of market insights.
Our passion is on achieving the Quintuple Aim of enhancing patient experience, improving population health, reducing costs, improving the work life of health care providers and staff., and enhancing health equity in all aspects of care delivery.
I’m Dr. Warren Smedley, thank you for joining us.
Petauri PACT Executive Briefings - 3-Minute Market Insights
Introduction to Targeted Therapies: Monoclonal Antibodies
Introduction to Targeted Therapies: Monoclonal Antibodies
Targeted Therapy is the foundation of Precision Medicine. Targeted therapy is a type of personalized treatment that targets specific proteins that control how cells grow, divide, and spread.
Antibodies are produced naturally by our body and help the immune system recognize cells that cause disease, such as bacteria and viruses, and mark them for destruction. Antibodies can be engineered in the laboratory to find and attach themselves to specific targets, called antigens, found on cancer cells. They are made to recognize and bind only to a very specific antigen target.
This week's episode highlights three important terms you may be hearing: Antibody-Drug Conjugates, Monoclonal Antibodies, and Bispecific Antibodies.
You can download the full Executive Briefing at: https://tkgpact.com/executive-briefings/
Or, feel free to email us at Insights@thekinetixgroup.com